"Efficacy and safety of peginterferon ?-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61383082%3A_____%2F11%3A0070" target="_blank" >RIV/61383082:_____/11:0070 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1097/MEG.0b013e32834b326b" target="_blank" >http://dx.doi.org/10.1097/MEG.0b013e32834b326b</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/MEG.0b013e32834b326b" target="_blank" >10.1097/MEG.0b013e32834b326b</a>

Result language
angličtina
Original language name
"Efficacy and safety of peginterferon ?-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe
Original language description
All patients in this open-label multinational study were assigned at the investigator'sdiscretion to receive peginterferon ?-2a (40 KD) 180 ?g/week plus ribavirin (800 mg/day) for a total of 24 weeks or peginterferon ?-2a (40 KD) 180 ?g/week plus ribavirin (1000/1200 mg/day) for a total of 48 weeks. Treatment success was defined as sustained virological response [sustained virological response (SVR); hepatitis C virus RNA less than 50 IU/ml after completion of untreated follow-up]. The combination of peginterferon ?-2a (40 KD) plus ribavirin was well tolerated and produced an overall SVR rate of 58% in treatment-naive patients. This study confirms that SVR rates achieved in pivotal clinical trials in Western Europe and the USA can be achieved in routine clinical practice in Central and Eastern Europe.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FE - Other fields of internal medicine
OECD FORD branch
—

Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)